CRC Clinical Trial
Official title:
The Effectiveness of WhatsApp Messenger on the Uptake of Colorectal Cancer Screening: a Non-inferiority Randomized Controlled Study
It is estimated that there are about 1.4 million patients with colorectal cancer (CRC) worldwide, with a rising trend in CRC incidence in many Asian Pacific countries1. In Hong Kong, colorectal cancer ranks first in cancer incidence and second in cancer mortality based on data from 20142. Recent guidelines from USA, Europe and Asia Pacific region recommend CRC screening for average-risk asymptomatic individuals starting at age 503-5. Modalities such as guaiac-based fecal occult blood tests (gFOBT), fecal immunochemical tests (FIT), flexible sigmoidoscopy (FS), and colonoscopy are among the acceptable options for CRC screening3-5. Department of Health of Hong Kong launched a Colorectal Cancer Screening Pilot Program in late 2016. This is a subsidized program offering primary care consultation with FIT. For those subjects with FIT positive, colonoscopy specialist consultation and colonoscopy will be arranged. The local uptake rate of CRC screening was reported to be 24.5%8 , which is relatively low when compared to other developed county9. In recent years, social media (SM) has become an increasingly popular source of health information10. By providing an easily accessible and interactive channel of communication between reviewers and information providers, it has potential values for affecting public health. However, the effects of SM on uptake of CRC screening has not yet been studied. WhatsApp Messenger, is the most popular social media messaging app worldwide. This randomized controlled study will investigate the effect of WhatsApp vs telephone intervention on the uptake of CRC screening.
Background It is estimated that there are about 1.4 million patients with colorectal cancer (CRC) worldwide, with a rising trend in CRC incidence in many Asian Pacific countries1. In Hong Kong, colorectal cancer ranks first in cancer incidence and second in cancer mortality based on data from 20142. Recent guidelines from USA, Europe and Asia Pacific region recommend CRC screening for average-risk asymptomatic individuals starting at age 503-5. Modalities such as guaiac-based fecal occult blood tests (gFOBT), fecal immunochemical tests (FIT), flexible sigmoidoscopy (FS), and colonoscopy are among the acceptable options for CRC screening3-5. Department of Health of Hong Kong launched a Colorectal Cancer Screening Pilot Program in late 2016. This is a subsidized program offering primary care consultation with FIT. For those subjects with FIT positive, colonoscopy specialist consultation and colonoscopy will be arranged. The local uptake rate of CRC screening was reported to be 24.5%8 , which is relatively low when compared to other developed county9. In recent years, social media (SM) has become an increasingly popular source of health information10. By providing an easily accessible and interactive channel of communication between reviewers and information providers, it has potential values for affecting public health. However, the effects of SM on uptake of CRC screening has not yet been studied. WhatsApp Messenger, is the most popular social media messaging app worldwide. This randomized controlled study will investigate the effect of WhatsApp vs telephone intervention on the uptake of CRC screening. Hypothesis Delivery of information of CRC screening program via SM can encourage uptake of CRC screening. Aim To investigate the effectiveness of Delivery of information of CRC screening program via WhatsApp on the uptake of CRC screening ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05002270 -
JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04557449 -
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04981119 -
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
|
||
| Active, not recruiting |
NCT01308086 -
Adjuvant Therapy(3 vs. 6 Months) With the FOLFOX 4 or XELOX for Stage II or Stage III Colon Cancer
|
Phase 3 | |
| Active, not recruiting |
NCT04585035 -
Study to Evaluate D-1553 in Subjects With Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT03665285 -
A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03336658 -
Intratumoral Budding (ITB) in Preoperative Biopsies of Colon and Rectal Cancer
|
||
| Terminated |
NCT03875313 -
Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05382377 -
NKG2D CAR-T(KD-025) in the Treatment of Advanced NKG2DL+ Solid Tumors
|
Early Phase 1 | |
| Active, not recruiting |
NCT05314309 -
Prospective Clinical Validation of a Novel Multitarget FIT in CRC Screening
|
||
| Recruiting |
NCT06259552 -
A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors
|
Phase 1 | |
| Completed |
NCT05976282 -
Addressing Colorectal Cancer in South Florida Firefighters
|
N/A | |
| Recruiting |
NCT01593098 -
A Prospective Study Into the Risk of Colorectal Neoplasms in Individuals With a Family History of Advanced Adenomas (Sibling AN Study)
|
||
| Recruiting |
NCT03597581 -
A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in 2nd Line RAS Mutant Advanced Colorectal Cancer
|
Phase 1 | |
| Terminated |
NCT05368688 -
Microbiome in Colorectal Cancer Onset and Progression
|
||
| Completed |
NCT03965845 -
A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT03601598 -
A Trial of SHR-1210 in Combination With SHR6390 in Patients With Advanced CRC, NSCLC and HCC
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05009329 -
FIH Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation in China
|
Phase 1/Phase 2 | |
| Completed |
NCT02161549 -
Evaluation of the Motus Gl CleanUp System During Screening Colonoscopy
|
N/A | |
| Active, not recruiting |
NCT04868773 -
Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy
|
Phase 1 |